Navigation Links
eClinical Solutions Teams with Karyopharm for COVID-19 Treatment Trial
Date:6/25/2020

eClinical Solutions LLC, a leading global provider of cloud-based enterprise software and software-driven clinical data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI) on randomized clinical trials for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first study of an XPO1 inhibitor in patients with severe viral infections. XPO1 inhibitors like selinexor (marketed as XPOVIO®) have previously shown preclinical activity against respiratory viruses, including SARS-CoV.

“The eClinical Solutions team is extremely motivated by the opportunity to contribute to finding new therapies that may treat COVID-19,” said Raj Indupuri, CEO of eClinical Solutions. “We are proud to partner with Karyopharm to support rapid data collection, cleaning and review for this program. The way they use modern technologies in clinical research to optimize data collection and analysis demonstrates their dedication to innovation not only in scientific research, but throughout the clinical development process.”

The eClinical Solutions Data Services team configured the data capture system for the trial using Medidata Rave EDC and the elluminate Clinical Data Platform for agile data management and review. The Karyopharm and eClinical Solutions teams collaborated closely to build a fully validated data database to collect data from physicians and patients in just 15 days—an accelerated timeline in order to meet the first patient milestone of this critical research initiative. The eClinical Solutions data management team is using elluminate Data Central to support data review activities for the study to ensure data is rapidly cleaned and available for medical and safety review.

“eClinical Solutions has been a valuable partner on other selinexor research programs. Their team’s knowledge of Karyopharm data standards and processes combined with their expertise in data collection platforms and clinical data management practices helped us meet our accelerated timelines for this important new research,” said Kristan Gallitano, SVP Development Operations at Karyopharm Therapeutics.

About eClinical Solutions
eClinical Solutions is a leading global provider of cloud-based enterprise software and software-driven clinical data services. The elluminate® platform provides life sciences companies with greater control of their clinical trial data. elluminate software and data-driven services have been used by more than 100 life sciences companies on more than 1000 trials. eClinical Solutions has worked with Karyopharm since 2015 to tech-enable a simplified data flow and help produce high quality data for more than 10 studies, including 5 database locks that provided the data for the July 2019 FDA approval of Karyopharm's lead compound XPOVIO® (selinexor). Learn more about eClinical Solutions and Karyopharm in this Case Study. For more information visit eclinicalsol.com.

About Karyopharm Therapeutics, Inc.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit http://www.karyopharm.com.

Read the full story at https://www.prweb.com/releases/eclinical_solutions_teams_with_karyopharm_for_covid_19_treatment_trial/prweb17214370.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. StageBio and Alizée Pathology join forces to meet the growing demand for high-quality histopathology and medical device services in the preclinical services market
2. Quartesian LLC Executes Multi-Year Enterprise Agreement with Medrio, Securing Access to Innovative eClinical Functionality and Support Services
3. Avastus Opens New Vivarium to Serve the Preclinical Research Needs of Boston’s Biotech Community
4. MedNet Solutions Announces Latest Release Of Its Award-Winning eClinical Solution
5. MedNet Solutions Named Most Outstanding eClinical Solutions Company
6. Clinlogix Strengthens Partnership With eClinical Technology Leader MedNet Solutions
7. MedNet Solutions iMedNet eClinical Wins Silver Stevie Award
8. Sponsors And CROs Rapidly Adopting MedNet Solutions eClinical Technology Platform
9. Quadrapeutics works in preclinical study of hard-to-treat tumors
10. MedNet Solutions Announces Latest Release Of Its Innovative iMedNet EDC eClinical Solution
11. Inflection Biosciences licenses preclinical oncology programs from the CNIO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2020)... ... June 04, 2020 , ... Murrieta Genomics ... new patent application for simplified sample preparation for Next Generation Genomic Sequencing (NGS) ... reduce cost, time, and complexity of sample preparation. , “I have been at the ...
(Date:5/28/2020)... ... May 27, 2020 , ... CrucialTrak, a global designer ... New Jersey-based Critical Environments Group (CEG) to market and sell its complete line of ... center and IT environment infrastructure optimization solutions . , Brett Mason, CrucialTrak’s ...
(Date:5/25/2020)... ... 2020 , ... Oxford Nanopore Technologies is in advanced development of a new ... COVID-19. , The LamPORE assay is designed to be rapid, low cost, ... numbers of samples. Hardware and reagents sit outside current, squeezed supply chains for ...
Breaking Biology News(10 mins):
(Date:5/30/2020)... ... 2020 , ... Medrio, Inc., the leading provider of eClinical ... Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics for conditions like ... in (FPI) in just seven days. The Cytovale technology will allow patients with ...
(Date:5/26/2020)... ... 2020 , ... Brilliant , the leading smart home control and lighting ... announce a new integration to bring more convenience, simplicity, and security to the smart ... Connect® can now be controlled from Brilliant’s in-wall touchscreen control panels and mobile app. ...
(Date:5/21/2020)... ... May 20, 2020 , ... ... Simon Prakash, who will serve as the company’s executive vice president of product ... when Exo is disrupting the medical imaging space, bringing more than 24 years ...
(Date:5/15/2020)... ... 15, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel ... Mr. Ganz will continue to lead Sentien’s Board of Directors, a role he ... Brian Miller and Sentien’s management team. , Mr. Ganz has more than ...
Breaking Biology Technology: